Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-100 plus Paclitaxel in Ovarian Cancer
NCT01485848Phase 2Completed
- Sponsor
- Esperance Pharmaceuticals, Inc.
- Start
- Feb 2012
- Primary completion
- May 2014
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of EP-100 in ovarian cancer, sponsored by Esperance Pharmaceuticals, Inc.. Started Feb 2012; status: completed.
02
Drugs
EP-100
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01485848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01485848.